CA Patent

CA3075877A1 — Method for producing retinal tissues

Assigned to Sumitomo Pharma Co Ltd · Expires 2019-03-21 · 7y expired

What this patent protects

The present invention addresses the problem of providing a method for suppressing differentiation of ganglion cells, amacrine cells, horizontal cells, and/or bipolar cells in neural retinal tissues including photoreceptor precursor cells and/or photoreceptor cells, etc. This meth…

USPTO Abstract

The present invention addresses the problem of providing a method for suppressing differentiation of ganglion cells, amacrine cells, horizontal cells, and/or bipolar cells in neural retinal tissues including photoreceptor precursor cells and/or photoreceptor cells, etc. This method for suppressing differentiation of ganglion cells, amacrine cells, horizontal cells, and/or bipolar cells in neural retinal tissues including photoreceptor precursor cells and/or photoreceptor cells comprises a step for culturing, in a medium containing a thyroid hormone signal transduction pathway active substance, retinal tissues that contains neural retinal precursor cells and are in any one of differentiation stages from a differentiation stage just after the emergence of ganglion cells to a stage at which the occurrence rate of pyramidal photoreceptor precursor cells reaches the maximum.

Drugs covered by this patent

Patent Metadata

Patent number
CA3075877A1
Jurisdiction
CA
Classification
Expires
2019-03-21
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.